Tesamorelin Dosage and Half-Life in the Research

The short version

In the trials, tesamorelin dosage was 2 mg injected under the skin once a day. The peptide itself clears the blood fast — a half-life (the time for half a dose to disappear) of roughly half an hour — but its downstream effect on IGF-1 lasts through the day, which is why once-daily dosing was studied. The notes below describe what researchers gave to which people, with figures cited. They are not instructions: research-grade tesamorelin is not an approved medicine to self-administer, and this site gives no human dosing advice.

The 2 mg/day regimen studied in trials

The tesamorelin dosage per day studied across the pivotal program was a single fixed amount. The canonical research dose is tesamorelin 2 mg administered subcutaneously once daily — the regimen used in both pivotal Phase 3 trials and the FDA-approved schedule ^[1][2]. A 1 mg/day dose was studied in a cognition trial and as a lower arm in a type-2-diabetes safety trial. Across these studies the 2 mg once-daily paradigm is the extensively characterized one.

The only route studied in clinical trials is subcutaneous injection at an abdominal site, which is also the only FDA-approved route ^[1]. Tesamorelin is supplied as a lyophilized powder requiring reconstitution; the label specifies refrigerated storage and use of the reconstituted solution within a defined window. These are descriptions of what was administered in research and in the labeled product, framed as studied at 2 mg/day in HIV patients — not a personal dosing instruction. There is no validated dose for any off-label use, because no large trial outside the HIV indication has been completed.

What is the half-life of tesamorelin?

The tesamorelin half life splits into two clocks: the peptide's and its downstream signal's. Plasma exposure is short. Population pharmacokinetic modeling reported apparent clearance of about 1,060 L/h with no clinically relevant demographic covariates ^[15]. Secondary sources — the FDA label and Mayo Clinic — describe a terminal half-life on the order of 26-38 minutes. Despite this rapid clearance, the downstream IGF-1 elevation persists across the dosing interval ^[4].

How long does tesamorelin stay in your system?

The peptide clears rapidly — apparent clearance about 1,060 L/h, terminal half-life roughly 26-38 minutes per secondary sources ^[15]. Its downstream effect on IGF-1, however, is sustained across the day, which is the pharmacologic rationale for a once-daily regimen ^[4].

Pharmacokinetics: rapid clearance, sustained signal

The pattern that defines tesamorelin's pharmacokinetics (how the body absorbs, distributes, and clears a drug) is a short-lived peptide producing a long-lived downstream effect. The trans-3-hexenoic acid N-terminal modification blocks the DPP-IV cleavage that inactivates native GHRH within minutes, extending the window in which tesamorelin can stimulate the pituitary ^[4]. Population modeling reported a roughly 13% increase in absorbed fraction by day 14 versus day 1 ^[15].

A population pharmacokinetic-pharmacodynamic analysis confirmed the growth-hormone secretion tesamorelin drives is episodic — pulsatile bursts rather than a flat elevation — and linked subcutaneous exposure to the growth-hormone and IGF-1 response ^[15]. This is why a peptide cleared in well under an hour can support once-daily dosing: the IGF-1 signal, not the peptide concentration, carries the effect through the day. The model found no clinically relevant demographic covariates on clearance, meaning age, sex, and weight did not shift the exposure enough to matter in the studied populations ^[15]. For how that signal translates to visceral and hepatic fat, see the GH/IGF-1 axis and the tesamorelin and liver fat findings.

Route and formulation studied

Every clinical-trial figure on this site rests on one route: subcutaneous injection at an abdominal site, the only route studied and the only FDA-approved one ^[1]. No oral, transdermal, or intranasal form has trial support, because the peptide would not survive gastrointestinal digestion intact — the same fragility that makes native GHRH short-lived applies to the route question.

The formulation reflects that fragility. Tesamorelin is supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use; the trans-3-hexenoic acid cap stabilizes the molecule against DPP-IV in circulation but does not make the dry-versus-dissolved handling trivial. The FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window ^[5]. These are descriptions of the labeled product and what trials administered, not handling instructions for self-administration — research-grade material sold for laboratory use carries none of the purity and potency oversight of the approved product.

Why dose figures are not a recommendation

The 2 mg/day and 1 mg/day figures throughout this page are study parameters, not guidance. They describe what investigators administered to specific populations — overwhelmingly HIV-positive adults on antiretroviral therapy — under monitored trial conditions ^[1][2]. The pivotal program established that 2 mg/day reduced visceral fat by 15.2% in that population ^[1]; it did not establish a dose for anyone outside it, because no large trial outside the HIV indication has been completed. Off-label use therefore has no validated dose, schedule, or monitoring protocol from the controlled literature. A qualified clinician, not a research digest, is the only appropriate source for any personal decision.